Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate to severe atopic dermatitis: results from the JADE REGIMEN phase 3 trial.

[1]  J. Silverberg,et al.  Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. , 2021, The New England journal of medicine.

[2]  C. Flohr,et al.  Efficacy and Safety of Abrocitinib in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN study , 2021 .

[3]  C. Banfield,et al.  Kinetic‐Pharmacodynamic Model of Platelet Time Course in Patients With Moderate‐to‐Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor Abrocitinib , 2020, CPT: pharmacometrics & systems pharmacology.

[4]  C. Flohr,et al.  Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial , 2020, The Lancet.

[5]  J. Silverberg,et al.  Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis , 2020, JAMA dermatology.

[6]  M. Ardeleanu,et al.  Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis† , 2019, The British journal of dermatology.

[7]  G. Yosipovitch,et al.  Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out? , 2016, Clinical Reviews in Allergy & Immunology.

[8]  L. Iversen,et al.  Tofacitinib withdrawal and retreatment in moderate‐to‐severe chronic plaque psoriasis: a randomized controlled trial , 2015, The British journal of dermatology.

[9]  L. Chan,et al.  The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis , 2013, JAK-STAT.

[10]  L. Coates,et al.  Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort , 2010, Arthritis care & research.

[11]  J. O’Shea,et al.  Janus kinases in immune cell signaling , 2009, Immunological reviews.

[12]  H. Williams,et al.  The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. , 2004, Archives of dermatology.

[13]  M. Graeber,et al.  The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis , 2001, Experimental dermatology.

[14]  A Y Finlay,et al.  The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use , 1995, The British journal of dermatology.

[15]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.

[16]  G. Rajka,et al.  Diagnostic Features of Atopic Dermatitis , 1980, Acta Dermato-Venereologica.

[17]  J. Silverberg,et al.  Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[18]  Julia Brasch,et al.  Severity Scoring of Atopic Dermatitis: The SCORAD Index , 1993 .